Revenue Up 13.7%
Operating Profit Up 20.5%
Dongkook Pharmaceutical achieved record-breaking results in the first quarter, with both revenue and operating profit increasing year-on-year.
According to the consolidated financial statements disclosed in the first quarter report on May 15, revenue reached 223.7 billion KRW and operating profit was 25.3 billion KRW, marking increases of 13.7% and 20.5%, respectively, compared to the same period last year.
This performance is attributed to improved efficiency in selling and administrative expenses resulting from increased revenue. In particular, the diversification of distribution channels underway in the healthcare business division is contributing to enhanced profitability. Dongkook Pharmaceutical plans to maintain its growth momentum by securing a future pipeline through open innovation, which will enable the development and launch of new products.
By business segment, all divisions?including the OTC business, ETC business, healthcare business, overseas business, and Dongkook Life Science (a subsidiary)?showed balanced growth. The OTC (over-the-counter) business division has continued to grow, driven by demand creation for existing brands and rapid growth in general product categories, despite challenging market conditions. The company is also working to expand new markets in pharmacies through pharmacy-exclusive cosmetics and pet product lines. By product, Insadol, Censia, Caritopotene, and general product categories all recorded double-digit or higher growth rates. In particular, Caritopotene has continued its high growth in the first quarter, following last year, by expanding its presence in the benign prostatic hyperplasia market in pharmacies as a growth driver.
In the ETC (ethical/the prescription drug) business division, four new products were launched in the first quarter of this year, contributing to revenue growth. In particular, sales of the company's injectable products stood out. Dongkook Pharmaceutical's top product, Lorelin, showed growth, while Hyalon, an HA intra-articular injection, recorded the largest growth in the musculoskeletal injectable product line.
In the healthcare business division, the company is leveraging its pharmaceutical heritage, technology, and expertise to launch consumer-friendly products across various fields, expand distribution channel infrastructure, and strengthen marketing. As a result, it is maintaining stable revenue trends in the beauty (cosmetics), online-focused growth, lifestyle health, and health food sectors. In particular, the company is actively conducting marketing activities in the overseas healthcare segment as a new growth driver.
In the beauty segment, the dermacosmetic brand 'Centellian24' is leading growth. With bestsellers such as the total anti-aging cream 'Madeca Cream' and the highly concentrated premium dark spot ampoule 'Expert Madeca Mela Capture Ampoule', the company is building a diverse lineup?including serums and mask packs?tailored to individual skin concerns.
In the lifestyle health segment, the company is continuing its strategy of expanding the domain of over-the-counter medicine brands into household goods. The company is strengthening brand competitiveness, focusing on Censian, Madeca, and Dentrix, among others.
In the health food business, 'Myfit' V/B/S series products based on nutraceuticals have surpassed cumulative sales of 25 billion KRW, establishing themselves as a core brand in the business segment. In January, the company launched 'Dongkook Pharmaceutical Health Mall', a health food specialty online mall, to provide customized solutions to customers, and is strengthening its brand presence by expanding distribution infrastructure through platforms such as Kakao.
The global business division, responsible for overseas (export) operations, has reorganized its business from the perspective of markets and customers, thereby solidifying its overseas business foundation. Key products such as the general anesthetic Popol injection and the antibiotic ingredient Teicoplanin are maintaining and strengthening their market positions in strategic markets. The company is preparing for revenue growth by expanding its business in the Central and South American markets. It is also actively developing new prescription drug markets for products such as Lorelin, Uresco, and Amphotericin B, and is securing future growth momentum by expanding its portfolio, including the overseas cosmetics business.
Dongkook Life Science was listed on KOSDAQ on February 17 this year and successfully settled into the stock market, recording a share price of 16,750 KRW and a corporate value of 270 billion KRW just three days after listing. Revenue is expected to reach 35.1 billion KRW, up 4.4% year-on-year, and operating profit is expected to be 3.1 billion KRW, up 8.1%. Dongkook Life Science plans to further enhance its corporate value by using the funds raised through its IPO to strengthen the acquisition of new growth engines.
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
